Home GPCR & G Protein Glucagon Receptor Agonist Semaglutide Sodium

research use only

Semaglutide Sodium Glucagon Receptor Agonist

Cat.No.: E7333

Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Semaglutide Sodium Glucagon Receptor Agonist Chemical Structure

Chemical Structure

Molecular Weight: 4113.58(free base)

Jump to

Quality Control

Batch: E733301 Water]100 mg/mL]false]DMSO]16 mg/mL]false]Ethanol]Insoluble]false Purity: 99.74%
99.74

Chemical Information, Storage & Stability

Molecular Weight 4113.58(free base) Formula

C187H291N45O59

 Storage (From the date of receipt)
CAS No. 910463-68-2(free base) -- Storage of Stock Solutions

Solubility

In vitro
Batch:

Water : 100 mg/mL

DMSO : 16 mg/mL
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
GLP1R
In vitro

Semaglutide is selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) is three-fold decreased compared to liraglutide, whereas the albumin affinity is increased.
In vivo

The plasma half-life is 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-19)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07772960 NOT_YET_RECRUITING
Alcohol Use Disorder (AUD); Obesity (BMI Equal to or >30)
Yale University
 2026-10-01 PHASE1
NCT06977438 NOT_YET_RECRUITING
Obesity, Childhood
University of Minnesota
 2026-10-01 PHASE4
NCT07731256 NOT_YET_RECRUITING
Lower Back Pain; Obesity (BMI>30); Chronic Lower Back Pain; glp1 Agonist
Washington University School of Medicine
 2027-02-01 PHASE2
NCT06934655 RECRUITING
Pediatric Obesity; Metabolic and Bariatric Surgery; Semaglutide
Children's Hospital Los Angeles
 2026-09-01 PHASE3
NCT07135245 NOT_YET_RECRUITING
Alzheimer Disease (AD)
Rune Skovgaard Rasmussen
 2026-01-01 PHASE2
NCT07090343 NOT_YET_RECRUITING
Aortic Stenosis; Heart Failure
Leiden University Medical Center
 2026-04-01 PHASE3